drugset / Trial / NCT06131437
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medicine will be gradually increased until reaching the planned dose (2.4 mg CagriSema or 15 mg Tirzepatide). The study will last for about one and a half year for each participant.
Timeline
- Start
- 2023-11-27
- Primary completion
- 2025-12-08
- Completion
- 2026-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cagrilintide | Protein / enzyme biologic | 2.4 mg | Subcutaneous |
| Subject | Semaglutide | Peptide | 2.4 mg | Subcutaneous |
| Comparator | Tirzepatide | Peptide | 15 mg | Subcutaneous |